Catheter Robotics, Inc. Completes Acquisition of VIVO Product Line; Changes its Name to Catheter Precision, Inc.

Mount Olive, NJ – May 24, 2016 – Catheter Robotics, Inc. (CRI) has announced that it has completed the acquisition of its new product line to be named VIVO. VIVO is a computerized three-dimensional cardiac mapping system showing electrical activation of the ventricles of the heart. VIVO stands for View Into Ventricular Onset.

In conjunction with the introduction of VIVO and moving into multiple product lines, CRI has chosen to change its name from Catheter Robotics, Inc. to Catheter Precision, Inc. Both the Amigo and VIVO products are oriented towards providing precision for catheter procedures in cardiac electrophysiology including both atrial fibrillation and ventricular arrhythmias.

Missiaen Huck, Director of Marketing of CRI commented, “With the acquisition of VIVO we are addressing an unmet need in cardiac EP. For the last ten to fifteen years, new catheter technologies have been focused on treating atrial fibrillation. Our new VIVO technology is for catheter treatment of ventricular arrhythmias, a disease treated generally by an expensive implantable defibrillator or by the lengthy catheter ablation procedures in a small number of centers. Our technology should allow the catheter procedures to be accepted and used on a general basis, even in the community hospitals. As such, this provides a game changer to fuel a much larger marketplace of the electrical malfunctions of the ventricles.”

Vivo allows the physician to accurately pinpoint the origin of a ventricular arrhythmia. The company intends to seek FDA approval later this year.